Advertisement

Der Urologe

pp 1–14 | Cite as

Sakrale Neuromodulation bei refraktärer überaktiver Blase

  • Arndt van Ophoven
CME
  • 12 Downloads

Zusammenfassung

Die sakrale Neuromodulation (SNM) ist eine minimalinvasive, etablierte Behandlungsmethode für die überaktive Blase („overactive bladder“, OAB) und weitere Beckenfunktionsstörungen, wie z. B. nichtobstruktive Retention oder Stuhlinkontinenz. Ein im oberen Gesäßbereich implantierter Schrittmacher gibt schwache elektrische Impulse an die Sakralnerven ab, sodass pathologische afferente Signale der pelvinen Endorgane moduliert werden. Der vorliegende Beitrag vermittelt den aktuellen Kenntnisstand zu Indikationen, Kontraindikationen, Wirkmechanismus, Implantationstechnik, Wirksamkeit und Komplikationen der SNM bei therapierefraktärer OAB.

Schlüsselwörter

Sakrale Neuromodulation Überaktive Blase Implantierte Stimulationselektroden Wirkmechanismus Wirksamkeit 

Sacral neuromodulation for refractory overactive bladder

Abstract

Sacral neuromodulation (SNM) is a minimally invasive, established treatment modality for overactive bladder (OAB) as well as for other pelvic functional disorders, such as non-obstructive urinary retention and fecal incontinence. A pacemaker implanted in the upper buttocks delivers mild electrical pulses to the sacral nerves thereby modulating pathological afferent signals from pelvic end organs. The current article conveys the current knowledge on the indications, contraindications, mechanism of action, implantation technique, efficacy and complications of SNM for the treatment refractory OAB.

Keywords

Sacral neuromodulation Overactive bladder Implanted stimulation electrodes Mechanism of action Efficacy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

A. van Ophoven hat in den letzten 5 Jahren Honorar für Beratertätigkeit und/oder Fortbildungsvorträge, ggf. inkl. Reisekostenerstattung von folgenden Firmen erhalten: Allergan, Apogepha, Astellas, Dr. Pfleger, Medtronic.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Tanagho EA, Schmidt RA (1982) Bladder pacemaker: scientific basis and clinical future. Urology 20(6):614–619PubMedCrossRefGoogle Scholar
  2. 2.
    Matzel KE, Chartier-Kastler E, Knowles CH, Lehur PA, Muñoz-Duyos A, Ratto C et al (2017) Sacral Neuromodulation: standardized electrode placement technique. Neuromodulation 20(8):816–824PubMedCrossRefGoogle Scholar
  3. 3.
    Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE et al (2018) Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral Neuromodulation. J Urol 199(1):229–236PubMedCrossRefGoogle Scholar
  4. 4.
    Datta SN, Chaliha C, Singh A, Gonzales G, Mishra VC, Kavia RB, Kitchen N, Fowler CJ, Elneil S (2008) Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int 101(2):192–196PubMedGoogle Scholar
  5. 5.
    Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, Madoff RD et al (2013) Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum 56(2):234–245PubMedCrossRefGoogle Scholar
  6. 6.
    Marcelissen T, Jacobs R, van Kerrebroeck P, de Wachter S (2011) Sacral neuromodulation as a treatment for chronic pelvic pain. J Urol 186(2):387–393PubMedCrossRefGoogle Scholar
  7. 7.
    Maeda Y, Kamm MA, Vaizey CJ, Matzel KE, Johansson C, Rosen H et al (2017) Long-term outcome of sacral neuromodulation for chronic refractory constipation. Tech Coloproctol 21(4):277–286PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Abrams P, Andersson KE, Birder L et al (2009) 4th international consultation on incontinence. Recommendations of the international scientific committee, 4. Aufl. Health Publication Ltd, Paris, France (Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence)Google Scholar
  9. 9.
    Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306–1314PubMedCrossRefGoogle Scholar
  10. 10.
    Irwin DE, Milsom I, Kopp Z, Abrams P, EPIC Study Group (2008) Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53(5):1029–1037CrossRefGoogle Scholar
  11. 11.
    Klotz T, Brüggenjürgen B, Burkart M, Resch A (2007) The economic costs of overactive bladder in Germany. Eur Urol 51(6):1654–1662PubMedCrossRefGoogle Scholar
  12. 12.
    Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, Tubaro A (2018) EAU guidelines. Edn. presented at the EAU annual congress copenhagen. http://uroweb.org/guideline/urinary-incontinence/#7 (ISBN 978-94-92671-01-1)Google Scholar
  13. 13.
    Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F et al (2017) Persistence and adherence with Mirabegron versus Antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol 72(3):389–399CrossRefGoogle Scholar
  14. 14.
    Balchandra P, Rogerson L (2014) Women’s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J 25(8):1059–1064PubMedCrossRefGoogle Scholar
  15. 15.
    Hashim H, Beusterien K, Bridges JF, Amos K, Cardozo L (2015) Patient preferences for treating refractory overactive bladder in the UK. Int Urol Nephrol 47(10):1619–1627PubMedCrossRefGoogle Scholar
  16. 16.
    Kessler TM, Maric A, Mordasini L, Wöllner J, Pannek J, Mehnert U et al (2014) Urologists’ referral attitude for sacral neuromodulation for treating refractory idiopathic overactive bladder syndrome: discrete choice experiment. Neurourol Urodyn 33(8):1240–1246PubMedCrossRefGoogle Scholar
  17. 17.
    Fontaine CL, Rudd I, Pakzad M, Hamid R, Ockrim JL, Greenwell TJ (2017) Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity. Urol Ann 9:249–252PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Goldman HB, Lloyd JC, Noblett KL, Carey MP, Castaño Botero JC, Gajewski JB et al (2018) International Continence Society best practice statement for use of sacral neuromodulation. Neurourol Urodyn.  https://doi.org/10.1002/nau.23515 PubMedCrossRefGoogle Scholar
  19. 19.
    Jones J, Van de Putte D, De Ridder D, Knowles C, O’Connell R, Nelson D et al (2016) A joint mechanism of action for sacral Neuromodulation for bladder and bowel dysfunction? Urology 97:13–19PubMedCrossRefGoogle Scholar
  20. 20.
    Malykhina AP, Wyndaele JJ, Andersson KE, De Wachter S, Dmochowski RR (2012) Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn 31(3):352–358PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Carrington EV, Knowles CH (2011) The influence of sacral nerve stimulation on anorectal dysfunction. Colorectal Dis 13(Suppl 2):5–9PubMedCrossRefGoogle Scholar
  22. 22.
    Kessler TM, Fowler CJ (2008) Sacral neuromodulation for urinary retention. Nat Clin Pract Urol 5(12):657–666PubMedCrossRefGoogle Scholar
  23. 23.
    Blok BF, Groen J, Bosch JL, Veltman DJ, Lammertsma AA (2006) Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 98(6):1238–1243PubMedCrossRefGoogle Scholar
  24. 24.
    Gourcerol G, Vitton V, Leroi AM, Michot F, Abysique A, Bouvier M (2011) How sacral nerve stimulation works in patients with faecal incontinence. Colorectal Dis 13(8):e203–e211PubMedCrossRefGoogle Scholar
  25. 25.
    Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J (2009) On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int 103(10):1324–1333PubMedCrossRefGoogle Scholar
  26. 26.
    Elkelini MS, Abuzgaya A, Hassouna MM (2010) Mechanisms of action of sacral neuromodulation. Int Urogynecol J 21(Suppl 2):439–446CrossRefGoogle Scholar
  27. 27.
    Melzack R, Wall PD (1965) Pain mechanisms: a new theory. Science 150:971–979CrossRefGoogle Scholar
  28. 28.
    Elneil S (2010) Urinary retention in women and sacral neuromodulation. Int Urogynecol J 21(Suppl 2):475–483CrossRefGoogle Scholar
  29. 29.
    Spinelli M, Sievert KD (2008) Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol 54(6):1287–1296PubMedCrossRefGoogle Scholar
  30. 30.
    Gallas S, Michot F, Faucheron JL, Meurette G, Lehur PA, Barth X et al (2011) Predictive factors for successful sacral nerve stimulation in the treatment of faecal incontinence: results of trial stimulation in 200 patients. Colorectal Dis 13(6):689–696PubMedCrossRefGoogle Scholar
  31. 31.
    Ghazwani YQ, Elkelini MS, Hassouna M (2011) Association between stimulation parameters and loss of efficacy of selective sacral nerve root stimulation. Neuromodulation 14(3):266–270PubMedCrossRefGoogle Scholar
  32. 32.
    Duelund-Jakobsen J, Laurberg S, Lundby L (2018) The functional outcome of sacral nerve stimulation for faecal incontinence can be improved by using lead model 3889 and a standardized implantation technique. Colorectal Dis 20(6):O152–O157PubMedCrossRefGoogle Scholar
  33. 33.
    Occhino JA, Siegel SW (2010) Sacral nerve modulation in overactive bladder. Curr Urol Rep 11(5):348–352PubMedCrossRefGoogle Scholar
  34. 34.
    Borawski KM, Foster RT, Webster GD, Amundsen CL (2007) Predicting implantation with a neuromodulator using two different test stimulation techniques: a prospective randomized study in urge incontinent women. Neurourol Urodyn 26(1):14–18PubMedCrossRefGoogle Scholar
  35. 35.
    Kessler TM, Madersbacher H, Kiss G (2005) Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method? Eur Urol 47(5):660–665PubMedCrossRefGoogle Scholar
  36. 36.
    Everaert K, Kerckhaert W, Caluwaerts H, Audenaert M, Vereecke H, De Cuypere G et al (2004) A prospective randomized trial comparing the 1‑stage with the 2‑stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol 45(5):649–654PubMedCrossRefGoogle Scholar
  37. 37.
    Cohen BL, Tunuguntla HS, Gousse A (2006) Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol 175(6):2178–2180PubMedCrossRefGoogle Scholar
  38. 38.
    Bolton JF, Harrison SC (2009) Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction? Curr Opin Urol 19:375–379PubMedCrossRefGoogle Scholar
  39. 39.
    Amend B, Khalil M, Kessler TM, Sievert KD (2011) How does sacral modulation work best? Placement and programming techniques to maximize efficacy. Curr Urol Rep 12(5):327–335PubMedCrossRefGoogle Scholar
  40. 40.
    Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW et al (1999) Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 162(2):352–357PubMedCrossRefGoogle Scholar
  41. 41.
    Weil EH, Ruiz-Cerdá JL, Eerdmans PH, Janknegt RA, Bemelmans BL, van Kerrebroeck PE (2000) Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol 37(2):161–171PubMedCrossRefGoogle Scholar
  42. 42.
    Hassouna MM, Siegel SW, Nÿeholt AA, Elhilali MM, van Kerrebroeck PE, Das AK, Gajewski JB, Janknegt RA, Rivas DA, Dijkema H, Milam DF, Oleson KA, Schmidt RA (2000) Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 163(6):1849–1854PubMedCrossRefGoogle Scholar
  43. 43.
    Groenendijk PM, Lycklama à Nyeholt AA, Heesakkers JP, van Kerrebroeck PE, Hassouna MM, Gajewski JB et al (2008) Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 101(3):325–329PubMedCrossRefGoogle Scholar
  44. 44.
    Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET et al (2015) Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6‑months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn 34(3):224–230PubMedCrossRefGoogle Scholar
  45. 45.
    Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT et al (2016) OnabotulinumtoxinA vs sacral Neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA 316(13):1366–1374PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF et al (2018) Two-year outcomes of sacral Neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol 74(1):66–73PubMedCrossRefGoogle Scholar
  47. 47.
    Kraus SR (2017) Sacral Neuromodulation is preferred over OnabotulinumtoxinA injection for overactive bladder in women: pro. J Urol 198(3):501–502PubMedCrossRefGoogle Scholar
  48. 48.
    Oerlemans DJ, van Kerrebroeck PE (2008) Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn 27(1):28–33PubMedCrossRefGoogle Scholar
  49. 49.
    van Voskuilen AC, Oerlemans DJ, Weil EH, de Bie RA, van Kerrebroeck PE (2006) Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol 49(2):366–372PubMedCrossRefGoogle Scholar
  50. 50.
    Burks FN, Diokno AC, Lajiness MJ, Ibrahim IA, Peters KM (2008) Sacral neuromodulation reprogramming: is it an office burden? Int Urogynecol J Pelvic Floor Dysfunct 19(8):1137–1140PubMedCrossRefGoogle Scholar
  51. 51.
    Noblett K, Siegel S, Mangel J, Griebling TL, Sutherland SE, Bird ET et al (2016) Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn 35(2):246–251PubMedCrossRefGoogle Scholar
  52. 52.
    Al-zahrani AA, Elzayat EA, Gajewski JB (2011) Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol 185(3):981–986PubMedCrossRefGoogle Scholar
  53. 53.
    Peters KM, Killinger KA, Gilleran JP, Bartley J, Wolfert C, Boura JA (2017) Predictors of reoperation after sacral neuromodulation: a single institution evaluation of over 400 patients. Neurourol Urodyn 36(2):354–359PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung für Neuro-UrologieMarien Hospital Herne, Universitätsklinikum der Ruhr-Universität BochumHerneDeutschland

Personalised recommendations